Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Jupiter spotlights critical advancement of JOTROL v conventional resveratrol

Jupiter Neurosciences (NASDAQ: JUNS) has highlighted the critical advancement of its proprietary resveratrol platform, JOTROL, compared to conventional resveratrol formulations, citing breakthrough bioavailability and...

July 23, 2025

Developments

EC grants marketing authorization for Autolus’ AUCATZYL for rr/B-ALL

Autolus Therapeutics (NASDAQ: AUTL) has announced that the European Commission (EC) has granted marketing authorization for AUCATZYL for the treatment of adult patients aged 26 and over with relapsed or refractory B...

July 21, 2025

Developments

USPTO grants Autonomix patent for smart torquer device

Autonomix Medical (NASDAQ: AMIX) has announced that the United States Patent and Trademark Office (USPTO) has issued a patent for its smart torquer device. The device is designed to enhance the manipulation of elongated...

July 21, 2025

Developments

Cuprina names Dr. Ronald Sherman as medical and scientific director; secures FDA-approved medical maggot license

Cuprina Holdings (NASDAQ: CUPR) has announced the appointment of Dr. Ronald Sherman, a leading innovator in maggot debridement therapy (MDT), as medical and scientific director, effective September 2025—securing the...

July 21, 2025

Developments

Knight files NDS for CREXONT in Canada

Knight Therapeutics (TSX: GUD) has announced that its new drug submission (NDS) for CREXONT—a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for the treatment of Parkinson’s disease—has...

July 18, 2025

Developments

Ekso Bionics launches virtual eksoUniversity to support CE for PTs and PTAs

Ekso Bionics (NASDAQ: EKSO) has announced the launch of eksoUniversity, a new platform providing continuing education (CE) courses to physical therapists (PTs) and physical therapy assistants (PTAs) across the U.S. Most...

July 18, 2025

Developments

Cognition’s positive data from Phase 2 study of zervimesine in DLB presented at AAIC

Cognition Therapeutics (NASDAQ: CGTX) has announced that James Edward Galvin, MD, MPH, will present results from the Phase 2 SHIMMER study of zervimesine (CT1812) in dementia with Lewy bodies (DLB) during an oral...

July 17, 2025

Developments

Revelation completes patient dosing in study of Gemini in CKC

Revelation Biosciences (NASDAQ: REVB) has announced the completion of dosing for its PRIME Phase 1b study of escalating doses of intravenously administered Gemini—a proprietary formulation of phosphorylated hexaacyl...

July 17, 2025

Developments

Cell One Partners’ video series: Dr. Stephen Chang reflects on 40 years of innovation in cell and gene therapy

In the latest episode of consulting company Cell One Partners’ video series—Cell One Insights—on cell and gene therapy, Stephen Chang, PhD—a human geneticist and partner at Cell One Partners—shares insights from his 40...

July 15, 2025

Developments

BiomX doses first patient in Phase 2b trial of BX004 in CF

BiomX (NYSE: PHGE) has announced the initiation of patient dosing in its Phase 2b trial evaluating BX004 for the treatment of cystic fibrosis (CF) patients with chronic pulmonary infections caused by Pseudomonas...

July 15, 2025

Developments

Firefly’s FDA-cleared BNA platform underpins groundbreaking precision neuroscience study with Heidelberg University

Firefly Neuroscience (NASDAQ: AIFF) has announced its continued collaboration with Prof. Christian Schaaf, MD, Director of the Institute of Human Genetics at Heidelberg University Hospital and Chairman of Human Genetics...

July 14, 2025

Developments

Oncogene publishes remission for testicular cancer patient treated with MiNK’s iNKT cell therapy

MiNK Therapeutics (NASDAQ: INKT) has highlighted a publication in the peer-reviewed journal Oncogene describing a complete and durable remission in a patient with metastatic, treatment refractory testicular cancer...

July 11, 2025

Developments

China’s NMPA approves Ascentage’s lisaftoclax for CLL/SLL

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855) has announced that China’s National Medical Products Administration (NMPA) has approved its proprietary novel Bcl-2 selective inhibitor lisaftoclax (APG-2575) for the...

July 10, 2025

Developments

PharmaJet enters MOU for needle-free vaccine delivery in Egypt

Closely held PharmaJet has announced the signing of a Memorandum of Understanding (MOU) with the Egyptian Unified Procurement Authority (UPA) and closely held EVA Pharma. The agreement aims to explore the integration of...

July 10, 2025

Developments

Cogent reports positive topline results from SUMMIT trial of bezuclastinib in NonAdvSM

Cogent Biosciences (NASDAQ: COGT) has announced positive topline results from the SUMMIT trial of bezuclastinib in patients with non-advanced systemic mastocytosis (NonAdvSM), achieving statistical significance across...

July 7, 2025

Developments

MedMira launches clinical trial for Multiplo TP/HIV self-test in Canada

MedMira (TSXV: MIR) has announced the launch of a clinical trial to evaluate its Multiplo TP/HIV rapid test for use as a self-test in Canada. Multiplo is a dual HIV and syphilis rapid self-test that delivers immediate...

July 7, 2025

Developments

Cyclacel highlights publication in Gut showing plogosertib is active in FLC

Cyclacel Pharmaceuticals (NASDAQ: CYCC; NASDAQ: CYCCP) has announced the publication of independent research in the peer-reviewed medical journal Gut demonstrating that plogosertib, a PLK1 inhibitor, is active in...

July 7, 2025

Developments

Cancer Cell highlights preclinical data of Tonix’s mTNX-1700 in gastric cancer models

Tonix Pharmaceuticals (NASDAQ: TNXP) has announced the publication of a paper in the peer-reviewed journal Cancer Cell, presenting data demonstrating that treatment with murine TNX-1700 (mTNX-1700) increased survival...

July 2, 2025

Developments

BriaCell adds two key clinical sites to Phase 3 study of lead candidate in MBC

BriaCell Therapeutics (NASDAQ: BCTX, BCTXW, BCTXZ; TSX: BCT) has announced the addition of two major cancer centers to its ongoing pivotal Phase 3 clinical study of Bria-IMT plus immune checkpoint inhibitor versus...

July 2, 2025

Developments

Clearmind doses first patient in trial of MEAI-based treatment for AUD

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that the first patient has been dosed in its Phase 1/2a clinical trial of its proprietary MEAI-based oral drug candidate, CMND-100, for the treatment of alcohol...

July 2, 2025

Developments

Medical City Dallas Hospital enhances surgical precision with Perimeter’s OCT imaging technology

Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) has announced that Medical City Dallas Hospital—an award-winning, 899-bed acute care hospital in the Dallas-Fort Worth area—has adopted the company’s current...

July 2, 2025

Developments

Artelo reports positive first-in-human results for novel non-opioid pain therapy

Artelo Biosciences (NASDAQ: ARTL) has announced positive results from its first-in-human study evaluating its novel non-opioid candidate, ART26.12, for the treatment of persistent pain. ART26.12 is the first orally...

June 30, 2025

Subscribe